Opendata, web and dolomites

STriTuVaD SIGNED

In Silico Trial for Tuberculosis Vaccine Development

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "STriTuVaD" data sheet

The following table provides information about the project.

Coordinator
ETNA BIOTECH SRL 

Organization address
address: STRADA VINCENZO LANCIA 57
city: CATANIA
postcode: 95100
website: www.etnabiotech.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.strituvad.eu
 Total cost 5˙050˙656 €
 EC max contribution 4˙549˙527 € (90%)
 Programme 1. H2020-EU.3.1.5. (Methods and data)
 Code Call H2020-SC1-2017-CNECT-2
 Funding Scheme RIA
 Starting year 2018
 Duration (year-month-day) from 2018-02-01   to  2022-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ETNA BIOTECH SRL IT (CATANIA) coordinator 1˙043˙750.00
2    INFECTIOUS DISEASE RESEARCH INSTITUTE US (SEATTLE WA) participant 1˙255˙027.00
3    UNIVERSITA DEGLI STUDI DI CATANIA IT (CATANIA) participant 909˙393.00
4    THE UNIVERSITY OF SHEFFIELD UK (SHEFFIELD) participant 465˙323.00
5    ARCHIVEL FARMA, SL ES (BADALONA) participant 408˙360.00
6    ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA IT (BOLOGNA) participant 402˙047.00
7    STICHTING TUBERCULOSIS VACCINE INITIATIVE NL (LELYSTAD) participant 65˙625.00
8    THE ALL-INDIA INSTITUTE OF MEDICAL SCIENCES IN (NEW DELHI) participant 0.00

Map

 Project objective

Tuberculosis (TB) one of the world’s deadliest diseases: one third of the world’s population, mostly in developing countries, is infected with TB. But TB is becoming again very dangerous also for developed countries, due to the increased mobility of the world population, and the appearance of several new bacterial strains that are multi-drug resistant (MDR). There is now a growing awareness that TB can be effectively fought only working globally, starting from countries like India, where the infection is endemic. Once a person present the active disease, the most critical issue is the current duration of the therapy, because of the high costs it involved, the increased chances of non-compliance (which increase the probability of developing an MDR strain), and the time the patient is still infectious to others. One exciting possibility to shorten the duration of the therapy are new host-reaction therapies (HRT) as a coadjuvant of the antibiotic therapy. The endpoints in the clinical trials for HRTs are time to inactivation, and incidence of recurrence. While for the first it is in some cases possible to have a statistically powered evidence for efficacy in a phase II clinical trial, recurrence almost always require a phase III clinical trial with thousands of patients involved, and huge costs. In the STriTuVaD project we will extend our Universal Immune System Simulator to include all relevant determinants of such clinical trial, establish its predictive accuracy against the individual patients recruited in the trial, use it to generate virtual patients and predict their response to the HRT being tested, and combine them to the observations made on physical patients using a new in silico-augmented clinical trial approach that uses a Bayesian adaptive design. This approach, where found effective could drastically reduce the cost of innovation in this critical sector of public healthcare.

 Deliverables

List of deliverables.
Report on the extensions implemented into the modeling simulation platform to reproduce the immune system – TBC – vaccines interactions and dynamics Documents, reports 2020-04-16 10:07:03
Report on the creation of the subjects-specific and virtual patients libraries that will be used in the implementation of the in silico clinical trial Documents, reports 2020-04-16 10:07:03
Governance and meetings: the governance bodies are set. SC meetings organised: logistic, preparation of programme, invitation of experts Documents, reports 2020-04-16 10:07:03
Report on the data collection and selection on TB disease and candidate vaccines/treatments Documents, reports 2020-04-16 10:07:03
First dissemination report Documents, reports 2020-04-16 10:07:03
Public web site Websites, patent fillings, videos etc. 2020-04-16 10:07:03
A coherent hierarchical Bayesian model encompassing the virtual and real data sources. Documents, reports 2020-04-16 10:07:03
Report on the modeling simulation framework able to simulate human immune system dynamics Documents, reports 2020-04-16 10:07:03
Dissemination plan Documents, reports 2020-04-16 10:07:03

Take a look to the deliverables list in detail:  detailed list of STriTuVaD deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STRITUVAD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STRITUVAD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.5.)

EUCAN-Connect (2019)

A federated FAIR platform enabling large-scale analysis of high-value cohort data connecting Europe and Canada in personalized health

Read More  

Instand-NGS4P (2020)

Integrated and standardized NGS workflows for Personalised therapy

Read More  

EUCANCan (2019)

EUCANCan: a federated network of aligned and interoperable infrastructures for the homogeneous analysis, management and sharing of genomic oncology data for Personalized Medicine.

Read More